Oncopeptides
Biotech firm developing targeted therapies for hematological cancers.
ONCO | ST
Overview
Corporate Details
- ISIN(s):
- SE0009414576 (+4 more)
- LEI:
- 549300J9WWQ5CBYQ1M77
- Country:
- Sweden
- Address:
- Luntmakargatan 46, 111 37 Stockholm
- Website:
- https://www.oncopeptides.com/en
- Sector:
- Manufacturing
Description
Oncopeptides is a biotechnology company focused on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company concentrates on hematological diseases, with a primary focus on multiple myeloma. Its commercialized product is Pepaxti (melflufen), a peptide-drug conjugate for adult patients with relapsed or refractory multiple myeloma. Founded in 2000 based on research from leading cancer institutions, Oncopeptides leverages its proprietary technology platforms to advance a pipeline of innovative drug candidates. The company's research also includes the development of Natural Killer (NK) cell engagers to address unmet medical needs in oncology.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2024-02-15 10:45 |
Oncopeptides ensures five years extended market exclusivity for Pepaxti in Euro…
|
English | PDF • 71.1 KB | ||
| 2024-02-15 10:45 |
Oncopeptides säkerställer förlängd marknadsexklusivitet för Pepaxti i Europa me…
|
Swedish | PDF • 72.0 KB | ||
| 2023-11-08 08:00 | Swedish | PDF • 628.7 KB | |||
| 2023-11-08 08:00 | English | PDF • 555.6 KB | |||
| 2023-10-20 08:30 |
Oncopeptides announces the Nomination Committee
|
English | PDF • 64.3 KB | ||
| 2023-10-20 08:30 |
Oncopeptides har utsett valberedningen
|
Swedish | PDF • 64.7 KB | ||
| 2023-09-29 08:00 |
Number of shares and votes in Oncopeptides
|
English | PDF • 67.9 KB | ||
| 2023-09-29 08:00 |
Antal aktier och röster i Oncopeptides
|
Swedish | PDF • 68.4 KB | ||
| 2023-09-28 11:15 |
Oncopeptides opts to abandon Type II variation process for Pepaxti to optimize …
|
English | PDF • 73.5 KB | ||
| 2023-09-28 11:15 |
Oncopeptides väljer att avsluta process för typ II-variation för Pepaxti i syft…
|
Swedish | PDF • 74.8 KB | ||
| 2023-09-14 15:50 |
CHMP issues positive opinion on Type II variation to extend the therapeutic ind…
|
English | PDF • 73.9 KB | ||
| 2023-09-14 15:50 |
CHMP ger positivt besked om typ II-variation för att utvidga den terapeutiska i…
|
Swedish | PDF • 75.0 KB | ||
| 2023-08-10 08:00 | Swedish | PDF • 732.4 KB | |||
| 2023-08-10 08:00 | English | PDF • 695.9 KB | |||
| 2023-08-09 08:40 |
Oncopeptides appoints Henrik Bergentoft as Chief Financial Officer
|
English | PDF • 70.3 KB |
Automate Your Workflow. Get a real-time feed of all Oncopeptides filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Oncopeptides
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Oncopeptides via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-04-15 | David Augustsson | Other | Buy | 1,250 | 6,350.00 SEK |
| 2024-04-15 | David Augustsson | Other | Buy | 1,250 | 6,312.50 SEK |
| 2024-04-15 | David Augustsson | Other | Buy | 438 | 2,225.04 SEK |
| 2024-04-15 | David Augustsson | Other | Buy | 60 | 303.60 SEK |
| 2024-04-15 | David Augustsson | Other | Buy | 2 | 10.02 SEK |
| 2023-09-08 | David Augustsson | Other | Buy | 2,296 | 17,706.75 SEK |
| 2023-08-10 | David Augustsson | Other | Buy | 1,704 | 14,995.20 SEK |
| 2023-05-04 | Nicolaas Bakker | Other | Buy | 5,000 | 42,380.00 SEK |
| 2022-10-10 | Nicolaas Bakker | Other | Buy | 15,000 | 164,400.00 SEK |
| 2022-08-30 | Per Wold-Olsen | Other | Buy | 2,050 | 55,350.00 SEK |
Peer Companies
